Primary Fibromyalgia Syndrome and 5-Hydroxy-L-Tryptophan: A 90-Day Open Study

1992 ◽  
Vol 20 (2) ◽  
pp. 182-189 ◽  
Author(s):  
P Sarzi Puttini ◽  
I Caruso
Keyword(s):  
Side Effects ◽  
Open Study ◽  
Fibromyalgia Syndrome ◽  
Laboratory Evaluation ◽  
Quality Of Sleep ◽  
Tender Points ◽  
Primary Fibromyalgia ◽  
Overall Evaluation ◽  
Primary Fibromyalgia Syndrome

The efficacy and tolerability of 5-hydroxy-L-tryptophan (5- HTP) were studied in an open 90-day study in 50 patients affected by primary fibromyalgia syndrome. When all the clinical variables studied throughout the trial (number of tender points, anxiety, pain intensity, quality of sleep, fatigue) were compared with baseline results, they all showed a significant improvement ( P< 0.001). The overall evaluation of the patient condition assessed by the patient and the investigator indicated a ‘good’ or ‘fair’ clinical improvement in nearly 50% of the patients during the treatment period. A total of 15 (30%) patients reported side-effects but only one patient was withdrawn from the treatment for this reason. No abnormality in the laboratory evaluation was observed. It is concluded that 5-HTP is effective in improving the symptoms of primary fibromyalgia syndrome and that it maintains its efficacy throughout the 90-day period of treatment.

Double-Blind Study of Dothiepin versus Placebo in the Treatment of Primary Fibromyalgia Syndrome

1987 ◽  
Vol 15 (3) ◽  
pp. 154-159 ◽  
Author(s):  
I. Caruso ◽  
P. C. Sarzi Puttini ◽  
L. Boccassini ◽  
S. Santandrea ◽  
M. Locati ◽  
...  
Keyword(s):  
Side Effects ◽  
Fibromyalgia Syndrome ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Clinical Variables ◽  
Primary Fibromyalgia ◽  
Significant Difference ◽  
Primary Fibromyalgia Syndrome

A double-blind study comparing the efficacy and tolerability of dothiepin with that of placebo in the treatment of primary fibromyalgia syndrome was carried out. Dothiepin was shown to improve significantly the condition of patients with primary fibromyalgia syndrome and there was a significant difference between dothiepin and placebo in all the clinical variables measured. Only mild and transient side-effects were reported. Further controlled studies are required to define the effects of dothiepin on fibromyalgia.

A Double-Blind Crossover Study of Two Cyclobenzaprine Regimens in Primary Fibromyalgia Syndrome

1993 ◽  
Vol 21 (2) ◽  
pp. 74-80 ◽  
Author(s):  
S Santandrea ◽  
F Montrone ◽  
P Sarzi-Puttini ◽  
L Boccassini ◽  
I Caruso
Keyword(s):  
Side Effects ◽  
Crossover Study ◽  
Fibromyalgia Syndrome ◽  
Double Blind ◽  
Primary Fibromyalgia ◽  
Significant Difference ◽  
Irritable Bowel ◽  
Primary Fibromyalgia Syndrome ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

In a double-blind crossover study, the efficacy and tolerability of oral cyclobenzaprine administered in two different regimens were compared in 40 patients affected by primary fibromyalgia syndrome. The patients were randomly divided into two groups. Each group of 20 patients was treated for 15 days with either a single dose of 10 mg/day cyclobenzaprine at bedtime or 30 mg/day cyclobenzaprine in three equal doses daily. Following treatment there was a 15-day washout period before the groups were crossed over to the other treatment. Both regimens resulted in a significant decline in the number of tender points; significant improvements were also reported in the quality of sleep, anxiety, fatigue, irritable bowel syndrome and stiffness. There was no significant difference in efficacy between the two therapeutic regimens at any stage during the trial. The frequency of reported side-effects was significantly greater ( P < 0.001) when patients received 30 mg/day cyclobenzaprine (26 patients, 84%) than when they received 10 mg/day (10 patients, 27%). A dose of 10 mg cyclobenzaprine at bedtime significantly improved the symptomatology of patients affected by primary fibromyalgia syndrome. The higher dose did not further reduce these symptoms but did result in a higher incidence of side-effects.

scholarly journals Juvenile primary Fibromyalgia Syndrome: epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Maya Levy Coles ◽  
Rotem Weissmann ◽  
Yosef Uziel
Keyword(s):  
Musculoskeletal Pain ◽  
Adolescent Girls ◽  
Fibromyalgia Syndrome ◽  
Clinical Manifestations ◽  
Pain Syndrome ◽  
Pain Processing ◽  
Tender Points ◽  
Primary Fibromyalgia ◽  
Primary Fibromyalgia Syndrome ◽  
Central Pain Processing

AbstractJuvenile primary fibromyalgia syndrome (JPFS) is a chronic, musculoskeletal pain syndrome affecting children and adolescents, most commonly adolescent girls. The syndrome has a multifactorial etiology, with altered central pain processing playing an important role. The hallmark symptom is severe, widespread musculoskeletal pain. Other symptoms include sleep and mood disturbances, headaches, stiffness, and subjective joint swelling. Physical examination can reveal multiple tender points. The diagnosis is clinical, with defined criteria. Early diagnosis and intervention are important. In this part of the review, we discuss the epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis of JPFS. Part two will focus on treatment and prognosis.

Within-Day Variability of Pain and Its Relation to Quality of Life in Children with Juvenile Primary Fibromyalgia Syndrome

MYOPAIN ◽  
2015 ◽  
Vol 23 (3-4) ◽  
pp. 165-171 ◽  
Author(s):  
Mona Sayed Ghaly ◽  
Nesrin M. Handouka ◽  
Abdelmoneim K. Khashana ◽  
Sherein A. Shalaby ◽  
Ayman E. Fahim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Fibromyalgia Syndrome ◽  
Primary Fibromyalgia ◽  
Primary Fibromyalgia Syndrome
Sign in / Sign up

Export Citation Format

Share Document